Brendan Coffey

Portfolio balance, sector exposure, and volatility differ sharply between these two funds. See which approach aligns with your global investment strategy.

Lockheed Martin leans on government contracts and the F-35, while RTX balances commercial and military sales with global reach and lower debt.

This North Carolina-based lender reported a notable insider sale while maintaining significant indirect ownership and a diversified business model.

One fund targets generative AI with active management, while the other tracks established tech giants. Explore how their strategies shape risk and growth.

Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.

Shares of this global avocado and mango supplier attracted a notable insider buy following a year of declining stock performance.

Compare portfolio makeup, sector weightings, and fund structure to see how these two popular ETFs stack up for long-term investors.

Compare portfolio strategies and sector exposures as two leading consumer staples ETFs take different paths to long-term returns.

Parabilis Medicines, a Cambridge, Massachusetts, biotech innovator in oncology, reported a notable insider buy amid ongoing development of cancer therapies.